all the information, none of the junk | biotech • healthcare • life sciences

BG Medicine, Bottomline, 4s3 Bioscience Among the Week’s Dealmakers

Partnership news, funding announcements, and an acquisition made up the New England deals news in the past week.

Concert Pharmaceuticals sold a worldwide license of its psychiatric drug to California-based Avanir Pharmaceuticals (NASDAQ: AVNR). The Lexington, MA-based biotech received an undisclosed upfront payment and is eligible for more than $200 million in additional sales and development milestones.

—Tata Motors, India’s largest automaker, enlisted Watertown, MA-based A123 Systems (NASDAQ: AONE) to supply the lithium-ion battery packs for its line of hybrid electric buses and other commercial vehicles.

—GE Capital Healthcare Financial Services announced that it provided Waltham, MA-based diagnostics company BG Medicine with a $15 million term loan facility. BG Medicine (NASDAQ: BGMD), which recently launched its BGM Galectin-3 test for heart failure patients, will use the money for commercialization and growth capital.

—Portsmouth, NH-based Bottomline Technologies (NASDAQ: EPAY), a maker of payment and invoice automation software, announced Monday that it will acquire the commercial banking business of Intuit (NASDAQ: INTU), as part of a new strategic partnership it formed with the Mountain View, CA-based financial software company. Financial terms of the deal were not disclosed.

—4s3 Bioscience, a Medford, MA-based maker of therapies for genetic diseases, nabbed $20 million in funding from KLP Enterprises to support development of its antibody technology.